Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Joachim, Höchel"'
Publikováno v:
Clinical Pharmacokinetics
Vilaprisan is a highly potent selective progesterone receptor modulator in development for the treatment of symptomatic uterine fibroids and endometriosis. Its pharmacokinetics are characterized by rapid absorption, almost complete bioavailability, a
Autor:
Maximilian Feldmüller, Joachim Höchel
Publikováno v:
Drug Research. 71:S8-S10
Autor:
Joachim Höchel, Christian Friedrich, Robert Fricke, Isabella Gashaw, Antje Rottmann, Kai Riecke, Herbert Wiesinger, Bettina Nowotny, Margarete Dr. Brudny-Klöppel, Stefan Klein
Publikováno v:
Clinical Pharmacology and Therapeutics
It is known that co‐administration of CYP3A inducers may decrease the effectiveness of oral contraceptives containing progestins as mono‐preparations or combined with ethinylestradiol. In a randomized clinical drug‐drug interaction study, we in
Autor:
Rüdiger Nave, Beate Rohde, Matthias Berse, Isabella Gashaw, Stefan Jodl, Jörn Krätzschmar, Anja Hoffmann, Frank S. Zollmann, Joachim Höchel
Publikováno v:
Reproductive Sciences. 26:523-531
BAY 1158061 is a potent monoclonal prolactin (PRL) receptor antibody, blocking PRL receptor (PRLR)-mediated signaling in a noncompetitive manner, which was tested in a randomized, placebo-controlled multiple dose study in postmenopausal women. The ob
Publikováno v:
Journal of Clinical Pharmacology
Intravaginal rings (IVRs) are an established option for continuous administration of drugs in women. The combination of anastrozole (ATZ) and levonorgestrel (LNG) in an IVR with an intended 4‐week wearing period has been considered for long‐term
Publikováno v:
Human reproduction (Oxford, England). 35(11)
STUDY QUESTION What is the reason for insufficient contraceptive efficacy of levonorgestrel (LNG) delivered by intravaginal ring (IVR) releasing comparable amounts of LNG as approved progestogen-only pills (POPs)? SUMMARY ANSWER The pharmacokinetic (
Autor:
Bart Ploeger, Tobias Kanacher, Sandra Ligges, Antje Rottmann, Marcus-Hillert Schultze-Mosgau, Manuela Casjens, Joachim Höchel, Niladri Chattopadhyay, Torsten Zimmermann, Sebastian Frechen
Publikováno v:
British Journal of Clinical Pharmacology. 84:2857-2866
Aims The primary aim of the present study was to quantify the effects of rifampicin, a strong cytochrome P450 (CYP) 3A4 inducer, on the pharmacokinetics of the new selective progesterone receptor modulator, vilaprisan. In addition, the effects of rif
Autor:
Diana L. Blithe, Vivek S. Purohit, Alison Edelman, Mohammad Ahsanul Akbar, Joachim Höchel, Erin Berry-Bibee, Ruth S. Day, Jim A. Turpin, Naomi K. Tepper, Myong-Jin Kim, David G. Strauss, Roxanne Jamshidi, Lei Zhang, Pamela E. Scott, Chongwoo Yu, Li Li, Haiying Sun
Publikováno v:
The Journal of Clinical Pharmacology. 58:1655-1665
Potential drug interactions with hormonal contraceptives are an important public health concern. A public meeting on "Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implication" was hosted by the United States Food
Autor:
Joachim Höchel
Publikováno v:
Drug research. 69(S 01)
Autor:
Masato Kaneko, Tero Jalkanen, Shunji Matsuki, Joachim Höchel, Rüdiger Nave, Christine Talling
Publikováno v:
Journal of Pharmaceutical Sciences. 107:1020-1027
Intravaginal rings (IVRs) are an option for continuous administration of drugs in women. However, a considerable amount of excess drug often remains in the ring upon removal. The current study focuses on comparing 2 IVRs releasing levonorgestrel (LNG